Trial Profile
A Phase IV Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Elective or Urgent Cardiac Surgery
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Postoperative infections; Surgical blood loss
- Focus Therapeutic Use
- Acronyms PREFER-CABG
- 19 Apr 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 19 Apr 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2022.
- 01 Nov 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.